Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Nevro Corp.
  6. News
  7. Summary
    NVRO   US64157F1030


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Nevro Announces Update in Patent Litigation with Boston Scientific

11/01/2021 | 05:33pm EST

REDWOOD CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, today announced that a Delaware jury found that Nevro infringed two Boston Scientific patents (7,891,085 and 8,019,439) directed to ways of manufacturing spinal cord stimulation (SCS) leads, which Nevro obtains from a third-party supplier.  Two other Boston Scientific lead patents (8,646,172 and 8,650,747) were not infringed.  The jury awarded Boston Scientific $20 million.  This decision has no commercial implications or would otherwise impose any restrictions on any current or future Nevro products, and the jury award is an amount of money that will not have a material impact on Nevro's business. 

"We disagree with the finding by the jury and plan to appeal," said Kashif Rashid, Nevro's General Counsel.

Nevro's Chairman and CEO, Keith Grossman, stated: "It is important to put this lawsuit into the proper context.  The suit regarding lead patents by Boston Scientific was in retaliation for the 2016 lawsuit Nevro filed to stop Boston Scientific from launching a 10kHz spinal cord stimulation system, which would blatantly and directly infringe Nevro's core intellectual property.  This lawsuit has absolutely no implications on Nevro's commercial efforts for current or planned products, and is directed to manufacturing methods implemented by our third-party supplier.  Nevro will continue to be the exclusive provider of HFX with 10 kHz Therapy, which the FDA determined to be superior to Boston Scientific's SCS therapy."

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain.  Nevro's proprietary 10 kHz Therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies.  The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary 10 kHz Therapy. 

SENZA, SENZA II, SENZA OMNIA, OMNIA, HF10, the HF10 logo, HFX, the HFX logo, HFX CONNECT, the HFX Connect logo, HFX ACCESS, the HFX Access logo, HFX COACH, the HFX Coach logo, HFX CLOUD, the HFX Cloud logo, RELIEF MULTIPLIED, the X logo, NEVRO, and the NEVRO logo are trademarks or registered trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com


View original content to download multimedia:https://www.prnewswire.com/news-releases/nevro-announces-update-in-patent-litigation-with-boston-scientific-301413427.html

SOURCE Nevro Corp.

ę PRNewswire 2021
All news about NEVRO CORP.
01/12Canaccord Genuity Adjusts Nevro's Price Target to $97 From $118, Reiterates Hold Rating
01/11UBS Adjusts Nevro Price Target to $94 From $110, Maintains Neutral Rating
01/10Nevro Increases Q4 2021 Revenue Guidance
01/10NEVRO : At JP Morgan 40th Annual Healthcare Conference
01/10NEVRO : Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue - Form ..
01/10Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
01/07Morgan Stanley Lowers Nevro to Equalweight From Overweight, Price Target to $100 From $..
01/07Piper Sandler Adjusts Nevro's Price Target to $92 From $90, Maintains Neutral Rating
01/04Health Care Stocks Stumble Through Weak Tuesday Session
01/04Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Tre..
More news
Analyst Recommendations on NEVRO CORP.
More recommendations